Direkt zum Inhalt

Ortmann, Olaf ; Schüler-Toprak, S. ; Kast, K. ; Fehm, T. ; Hahne, A. ; Huber, D. ; Kühnle, E. ; Mohr, K. ; Rhiem, K. ; Seitz, S. ; Speiser, D.

The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer

Ortmann, Olaf , Schüler-Toprak, S., Kast, K., Fehm, T., Hahne, A., Huber, D., Kühnle, E., Mohr, K., Rhiem, K., Seitz, S. und Speiser, D. (2024) The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. Journal of Cancer Research and Clinical Oncology 150 (9).

Veröffentlichungsdatum dieses Volltextes: 24 Sep 2024 05:56
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.59200


Zusammenfassung

Purpose To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions. Methods Evidence on the safety of endocrine interventions for fertility treatment, contraception, hormone replacement therapy after risk-reducing salpingo-oophorectomy (RRSO) or treatment of symptoms during peri- and postmenopause was analysed for carriers ...

Purpose
To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions.
Methods
Evidence on the safety of endocrine interventions for fertility treatment, contraception, hormone replacement therapy after risk-reducing salpingo-oophorectomy (RRSO) or treatment of symptoms during peri- and postmenopause was analysed for carriers of probably pathogenic and pathogenic variants in BRCA1 or BRCA2 (BRCA1/2-pV), in other breast and ovarian cancer genes and the Lynch Syndrome. Cancer risks were compared with data on risks for the general population.
Results
Data on risk modulation of endocrine interventions in women with genetic predisposition is limited. Ovarian hyperstimulation for fertility treatment may be performed. Oral contraceptives should not be used to reduce ovarian cancer risk in BRCA1/2-pV carriers. Premenopausal BRCA1/2-pV carriers and carriers of pV in Lynch Syndrome genes should be offered hormone replacement therapy (HRT) after RRSO, to prevent diseases caused by estrogen deficiency.
Conclusion
Effect direction and strength of risk modulation by endocrine interventions is similar to the general population. Participation of individuals at risk in prospective registries is recommended.



Beteiligte Einrichtungen


Details

DokumentenartArtikel
Titel eines Journals oder einer ZeitschriftJournal of Cancer Research and Clinical Oncology
Verlag:Springer
Band:150
Nummer des Zeitschriftenheftes oder des Kapitels:9
Datum11 September 2024
InstitutionenMedizin > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde)
Identifikationsnummer
WertTyp
10.1007/s00432-024-05936-7DOI
Stichwörter / KeywordsOral contraception · Fertility treatment · Hormone therapy · BRCA1 and BRCA2 · Breast cancer · Ovarian cancer
Dewey-Dezimal-Klassifikation600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
StatusVeröffentlicht
BegutachtetJa, diese Version wurde begutachtet
An der Universität Regensburg entstandenZum Teil
URN der UB Regensburgurn:nbn:de:bvb:355-epub-592005
Dokumenten-ID59200

Bibliographische Daten exportieren

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

nach oben